Epidemiology of Peripheral Vascular Disease

  • Edward J. Boyko
  • Nicholas L. Smith
  • Jessie H. Ahroni
Part of the Contemporary Cardiology book series (CONCARD)


The epidemiology of several arterial diseases is covered in this chapter. Peripheral vascular disease (PVD) refers to arterial disease affecting the extremities, and this chapter also focuses on some other aspects of PVD, including measurement of outcomes such as functional status and quality of life, associated conditions, and mortality. In addition, the epidemiology of carotid/vertebral system disease (CVD) and coronary artery disease (CAD) is discussed.


Coronary Heart Disease Peripheral Arterial Disease Peripheral Vascular Disease Arterial Disease Intermittent Claudication 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Boyko EJ, Alderman BW, Baron AE. Reference test errors bias the evaluation of diagnostic tests for ischemic heart disease. J Gen Intern Med 1988;3:476–481.PubMedCrossRefGoogle Scholar
  2. 2.
    Young MJ, Adams JE, Anderson GF, Boulton AJ, Cavanagh PR. Medial arterial calcification in the feet of diabetic patients and matched non-diabetic control subjects. Diabetologia 1993;36:615–621.PubMedCrossRefGoogle Scholar
  3. 3.
    Rothman KJ, Greenland S. Modern Epidemiology. Lippincott-Raven, Philadelphia, 1998, pp. 86–89.Google Scholar
  4. 4.
    Meijer WT, Hoes AW, Rutgers D, Bots ML, Hofman A, Grobbee DE. Peripheral arterial disease in the elderly: the Rotterdam Study. Arterioscler Thromb Vasc Biol 1998;18:185–192.PubMedCrossRefGoogle Scholar
  5. 5.
    Curb JD, Masaki K, Rodriguez BL, et al. Peripheral artery disease and cardiovascular risk factors in the elderly. The Honolulu Heart Program. Arterioscler Thromb Vasc Biol 1996;16:1495–1500.PubMedCrossRefGoogle Scholar
  6. 6.
    Criqui MH, Denenberg JO, Langer RD, Fronek A. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med 1997;2:221–226.PubMedGoogle Scholar
  7. 7.
    Leng GC, Fowkes FG. The Edinburgh Claudication Questionnaire: an improved version of the WHO/ Rose Questionnaire for use in epidemiological surveys. J Clin Epidemiol 1992;45:1101–1109.PubMedCrossRefGoogle Scholar
  8. 8.
    Fowkes FG. Epidemiology of peripheral vascular disease. Atherosclerosis 1997;131(Suppl):S29–S31.CrossRefGoogle Scholar
  9. 9.
    Hale WE, Marks RG, May FE, Moore MT, Stewart RB. Epidemiology of intermittent claudication: evaluation of risk factors. Age Ageing 1988;17:57–60.PubMedCrossRefGoogle Scholar
  10. 10.
    Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol 1976;38:46–51.PubMedCrossRefGoogle Scholar
  11. 11.
    Fowkes FG, Housley E, Riemersma RA, et al. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol 1992;135:331–340.PubMedGoogle Scholar
  12. 12.
    Price JF, Mowbray PI, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J 1999;20:344–353.PubMedCrossRefGoogle Scholar
  13. 13.
    Newman AB, Siscovick DS, Manolio TA, et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation 1993;88:837–845.PubMedCrossRefGoogle Scholar
  14. 14.
    Halperin JL, Creager MA. Arterial obstructive diseases of the extremities. In: Loscalzo J, Creager MA, Dzau VJ, eds. Vascular Medicine. Little, Brown, Boston, 1992, pp. 835–865.Google Scholar
  15. 15.
    LoGerfoFW,CoffmanJD.Currentconcepts.Vascularandmicrovasculardiseaseofthefootindiabetes. Implications for foot care. N Engl J Med 1984;311:1615–1619.CrossRefGoogle Scholar
  16. 16.
    Liese AD, Mayer-Davis EJ, Haffner SM. Development of the multiple metabolic syndrome: an epidemiologic perspective. Epidemiol Rev 1998;20:157–172.PubMedCrossRefGoogle Scholar
  17. 17.
    Lee AJ, MacGregor AS, Hau CM, et al. The role of haematological factors in diabetic peripheral arterial disease: the Edinburgh artery study. Br J Haematol 1999;105:648–654.PubMedCrossRefGoogle Scholar
  18. 18.
    Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. J Am Geriatr Soc 1985;33:13–18.PubMedGoogle Scholar
  19. 19.
    Ogren M, Hedblad B, Isacsson SO, Janzon L, Jungquist G, Lindell SE. Noninvasively detected carotid stenosis and ischaemic heart disease in men with leg arteriosclerosis. Lancet 1993;342:1138–1141.PubMedCrossRefGoogle Scholar
  20. 20.
    Aschoff L. Observations concerning the relationship between cholesterol metabolism and vascular disease. BMJ 1932;2:1121.CrossRefGoogle Scholar
  21. 21.
    Malinow MR, Kang SS, Taylor LM, et al. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation 1989;79:1180–1188.PubMedCrossRefGoogle Scholar
  22. 22.
    Robinson K, Arheart K, Refsum H, et al. Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group. Circulation 1998;97:437–443.PubMedCrossRefGoogle Scholar
  23. 23.
    Lowe GD, Fowkes FG, Dawes J, Donnan PT, Lennie SE, Housley E. Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study. Circulation 1993;87:1915–1920.PubMedCrossRefGoogle Scholar
  24. 24.
    Lee AJ, Fowkes FG, Lowe GD, Rumley A. Fibrin D-dimer, haemostatic factors and peripheral arterial disease. Thromb Haemost 1995;74:828–832.PubMedGoogle Scholar
  25. 25.
    Cook PJ, Lip GY. Infectious agents and atherosclerotic vascular disease. Q J Med 1996;89:727–735.CrossRefGoogle Scholar
  26. 26.
    Gibbs RG, Carey N, Davies AH. Chlamydiapneumoniae and vascular disease. Br J Surg 1998;85:1191–1197.PubMedCrossRefGoogle Scholar
  27. 27.
    Martyn CN, Gale CR, Jespersen S, Sherriff SB. Impaired fetal growth and atherosclerosis of carotid and peripheral arteries. Lancet 1998;352:173–178.PubMedCrossRefGoogle Scholar
  28. 28.
    Hales CN, Desai M, Ozanne SE. The Thrifty Phenotype hypothesis: how does it look after 5 years? Diabetes Med 1997;14:189–195.CrossRefGoogle Scholar
  29. 29.
    BaintonD,SweetnamP,BakerI,ElwoodP.Peripheralvasculardisease:consequenceforsurvivalandassociation with risk factors in the Speedwell prospective heart disease study. Br Heart J 1994;72:128–132.Google Scholar
  30. 30.
    von Kemp K, van den Brande P, Peterson T, et al. Screening for concomitant diseases in peripheral vascular patients. Results of a systematic approach. Int Angiol 1997;16:114–122.Google Scholar
  31. 31.
    Allan PL, Mowbray PI, Lee AJ, Fowkes FG. Relationship between carotid intima-media thickness and symptomatic and asymptomatic peripheral arterial disease. TheEdinburgh Artery Study. Stroke 1997;28: 348–353.PubMedCrossRefGoogle Scholar
  32. 32.
    Peabody CN, Kannel WB, McNamara PM. Intermittent claudication. Surgical significance. Arch Surg 1974;109:693–697.PubMedCrossRefGoogle Scholar
  33. 33.
    Szilagyi DE, Hageman JH, Smith RF, Elliott JP, Brown F, Dietz P. Autogenous vein grafting in femoropopliteal atherosclerosis: the limits of its effectiveness. Surgery 1979;86:836–851.PubMedGoogle Scholar
  34. 34.
    DeWeese JA, Rob CG. Autogenous venous grafts ten years later. Surgery 1977;82:755–784.PubMedGoogle Scholar
  35. 35.
    Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381–386.PubMedCrossRefGoogle Scholar
  36. 36.
    Simonsick EM, Guralnik JM, Hennekens CH, Wallace RB, Ostfeld AM. Intermittent claudication and subsequent cardiovascular disease in the elderly. J Gerontol A Biol Sci Med Sci 1995;50A:M17–M22.CrossRefGoogle Scholar
  37. 37.
    Howell MA, Colgan MP, Seeger RW, Ramsey DE, Sumner DS. Relationship of severity of lower limb peripheral vascular disease to mortality and morbidity: a six-year follow-up study. J Vasc Surg 1989;9: 691–697.PubMedGoogle Scholar
  38. 38.
    Bauman HC, Arthur HM. Relationship between functional exercise capacity and general quality of life in nonsurgical patients with lower-extremity peripheral arterial disease. J Vasc Nurs 1997;15:21–28.PubMedCrossRefGoogle Scholar
  39. 39.
    Ouriel K, Fiore WM, Geary JE. Limb-threatening ischemia in the medically compromised patient: amputation or revascularization? Surgery 1988;104:667–672.PubMedGoogle Scholar
  40. 40.
    Hiatt WR. Quality of life assessment in peripheral arterial disease. Atherosclerosis 1997;131(Suppl): S35–S36.CrossRefGoogle Scholar
  41. 41.
    Whyman MR, Fowkes FG, Kerracher EM, et al. Is intermittent claudication improved by percutaneous transluminal angioplasty? A randomized controlled trial. J Vasc Surg 1997;26:551–557. 42. Regensteiner JG, Hargarten ME, Rutherford RB, Hiatt WR. Functional benefits of peripheral vascular bypass surgery for patients with intermittent claudication. Angiology 1993;44:1–10.Google Scholar
  42. 43.
    McDermott MM, Liu K, Guralnik JM, Martin GJ, Criqui MH, Greenland P. Measurement of walking endurance and walking velocity with questionnaire: validation of the walking impairment questionnaire in men and women with peripheral arterial disease. J Vasc Surg 1998;28:1072–1081.PubMedCrossRefGoogle Scholar
  43. 44.
    Sallis JF, Haskell WL, Wood PD, et al. Physical activity assessment methodology in the Five-City Project. Am J Epidemiol 1985;121:91–106.PubMedGoogle Scholar
  44. 45.
    Arfvidsson B, Karlsson J, Dahllof AG, Lundholm K, Sullivan M. The impact of intermittent claudication on quality of life evaluated by the Sickness Impact Profile technique. EurJ Clin Invest 1993;23:741–745.CrossRefGoogle Scholar
  45. 46.
    Thompson MM, Sayers RD, Reid A, Underwood MJ, Bell PR. Quality of life following infragenicular bypass and lower limb amputation. Eur J Vasc Endovasc Surg 1995;9:310–313. 47. Spitzer WO, Dobson AJ, Hall J, et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chron Dis 1981;34:585–597.CrossRefGoogle Scholar
  46. 48.
    Albers M, Fratezi AC, De Luccia N. Assessment of quality of life of patients with severe ischemia as a result of infrainguinal arterial occlusive disease. J Vasc Surg 1992;16:54–59.PubMedCrossRefGoogle Scholar
  47. 49.
    Ware JE Jr. Methodology in behavioral and psychosocial cancer research. Conceptualizing disease impact and treatment outcomes. Cancer 1984;53:2316–2326.PubMedGoogle Scholar
  48. 50.
    Schneider JR, McHorney CA, Malenka DJ, McDaniel MD, Walsh DB, Cronenwett JL. Functional health and well-being in patients with severe atherosclerotic peripheral vascular occlusive disease. Ann Vasc Surg 1993;7:419–428.PubMedCrossRefGoogle Scholar
  49. 51.
    Bruni KR, Hoosier-Paty DM, Hoffman GT. The quality of life of the limb-threatened patient after lowerextremity revascularization. J Vasc Nurs 1996;14:99–103.PubMedCrossRefGoogle Scholar
  50. 52.
    Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Fihn SD. Monitoring the quality of life in patients with coronary artery disease. Am J Cardiol 1994;74:1240–1244.PubMedCrossRefGoogle Scholar
  51. 53.
    Hankey GJ. Stroke: how large a public health problem, and how can the neurologist help? Arch Neurol 1999;56:748–754.PubMedCrossRefGoogle Scholar
  52. 54.
    Wagenknecht LE, D’Agostino RB Jr, Haffner SM, Savage PJ, Rewers M. Impaired glucose tolerance, type 2 diabetes, and carotid wall thickness: the Insulin Resistance Atherosclerosis Study. Diabetes Care 1998;21:1812–1818.PubMedCrossRefGoogle Scholar
  53. 55.
    Howard G, O’Leary DH, Zaccaro D, et al. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators [see comments]. Circulation 1996;93:1809–1817.PubMedCrossRefGoogle Scholar
  54. 56.
    Sharrett AR, Sorlie PD, Chambless LE, et al. Relative importance of various risk factors for asymptomatic carotid atherosclerosis versus coronary heart disease incidence: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 1999;149:843–852.PubMedCrossRefGoogle Scholar
  55. 57.
    Ebrahim S, Papacosta O, Whincup P, et al. Carotid plaque, intima media thickness, cardiovascular risk factors, and prevalent cardiovascular disease in men and women: the British Regional Heart Study. Stroke 1999;30:841–850.PubMedCrossRefGoogle Scholar
  56. 58.
    Anonymous. Decline in deaths from heart disease and stroke United States. 1900–1999. MMWR 1999;48:649–656.Google Scholar
  57. 59.
    Anonymous. Death: Final data for 1997. Natl Vital Stat Rep 1999;47.Google Scholar
  58. 60.
    Anonymous. Changes in mortality from heart failure United States. 1980–1995. MMWR 1998;47: 633–637.Google Scholar
  59. 61.
    Croft JB, Giles WH, Pollard RA, Casper ML, Anda RF, Livengood JR. National trends in the initial hospitalization for heart failure. J Am Geriatr Soc 1997;45:270–275.PubMedGoogle Scholar
  60. 62.
    Dawber TR, Kannel WB. The Framingham study. An epidemiological approach to coronary heart disease. Circulation 1966;34:553–555.PubMedCrossRefGoogle Scholar
  61. 63.
    Friedman GD, Cutter GR, Donahue RP, et al. CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol 1988;41:1105–1116.PubMedCrossRefGoogle Scholar
  62. 64.
    Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991;1:263–276.PubMedCrossRefGoogle Scholar
  63. 65.
    Anonymous. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol 1989;129:687–702.Google Scholar
  64. 66.
    Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333: 1301–1307.PubMedCrossRefGoogle Scholar
  65. 67.
    Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615–1622.PubMedCrossRefGoogle Scholar
  66. 68.
    Anonymous. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–1389.Google Scholar
  67. 69.
    Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998;279:1643–1650.PubMedCrossRefGoogle Scholar
  68. 70.
    Kawachi I, Colditz GA, Stampfer MJ, et al. Smoking cessation and time course of decreased risks of coronary heart disease in middle-aged women. Arch Intern Med 1994;154:169–175.PubMedCrossRefGoogle Scholar
  69. 71.
    Kuller LH, Ockene JK, Meilahn E, Wentworth DN, Svendsen KH, Neaton JD. Cigarette smoking and mortality. MRFIT Research Group. Prey Med 1991;20:638–654.CrossRefGoogle Scholar
  70. 72.
    Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971–1993. Diabetes Care 1998;21:1138–1145.PubMedCrossRefGoogle Scholar
  71. 73.
    Abraira C, Colwell J, Nuttall F, et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med 1997;157:181–188.PubMedCrossRefGoogle Scholar
  72. 74.
    Anonymous. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837–853.CrossRefGoogle Scholar
  73. 75.
    Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999; 281:1291–1297.PubMedCrossRefGoogle Scholar
  74. 76.
    Anonymous. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ 1992;304:405–412.CrossRefGoogle Scholar
  75. 77.
    Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993;270:713–724.PubMedCrossRefGoogle Scholar
  76. 78.
    Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757–764.PubMedCrossRefGoogle Scholar
  77. 79.
    Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 Study. Lancet 1999;354:1751–1756.PubMedCrossRefGoogle Scholar
  78. 80.
    Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens 1996;9:342–360.PubMedCrossRefGoogle Scholar
  79. 81.
    HanssonL,ZanchettiA,CarruthersSG,etal.Effectsofintensiveblood-pressureloweringandlow-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755–1762.Google Scholar
  80. 82.
    Siscovick DS, Raghunathan TE, Psaty BM, et al. Diastolic blood pressure and the risk of primary cardiac arrest among pharmacologically treated hypertensive patients. J Gen Intern Med 1996;11:350–356.PubMedCrossRefGoogle Scholar
  81. 83.
    Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP. The spread of the obesity epidemic in the United States, 1991–1998. JAMA 1999;282:1519–1522.PubMedCrossRefGoogle Scholar
  82. 84.
    Powell KE, Thompson PD, Caspersen CJ, Kendrick JS. Physical activity and the incidence of coronary heart disease. Annu Rev Public Health 1987;8:253–287.PubMedCrossRefGoogle Scholar
  83. 85.
    Eaton CB. Relation of physical activity and cardiovascular fitness to coronary heart disease, Part I: A meta-analysis of the independent relation of physical activity and coronary heart disease. J Am Board Fam Pract 1992;5:31–42.Google Scholar
  84. 86.
    Manson JE, Hu FB, Rich-Edwards JW, et al. A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. N Engl J Med 1999;341:650–658.PubMedCrossRefGoogle Scholar
  85. 87.
    Barrett-Connor EL. Obesity, atherosclerosis, and coronary artery disease. Ann Intern Med 1985;103: 1010–1019.CrossRefGoogle Scholar
  86. 88.
    Schulte H, Cullen P, Assmann G. Obesity, mortality and cardiovascular disease in the Munster Heart Study (PROCAMMM). Atherosclerosis 1999;144:199–209.PubMedCrossRefGoogle Scholar
  87. 89.
    Lempiainen P, Mykkanen L, Pyorala K, Laakso M, Kuusisto J. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation 1999;100:123–128.PubMedCrossRefGoogle Scholar
  88. 90.
    Anonymous. Coronary heart disease incidence, by sex United States, 1971–1987. MMWR Morb Mortal Wkly Rep 1992;41:526–529.Google Scholar
  89. 91.
    Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation 1999;99:1165–1172.PubMedCrossRefGoogle Scholar
  90. 92.
    Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease [published erratum appears in N Engl J Med 1996 Oct 31;335(18):1406]. N Engl J Med 1996;335:453–461.Google Scholar
  91. 93.
    Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605–613.PubMedCrossRefGoogle Scholar
  92. 94.
    Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985;313:1044–1049.PubMedCrossRefGoogle Scholar
  93. 95.
    Breslow JL. Genetics of lipoprotein disorders. Circulation 1993;87:III16–III21.Google Scholar
  94. 96.
    Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844–2850.PubMedCrossRefGoogle Scholar
  95. 97.
    Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation 1999;99:2901–2907.PubMedCrossRefGoogle Scholar
  96. 98.
    Andrieu N, Goldstein AM. Epidemiologic and genetic approaches in the study of gene-environment interaction: an overview of available methods. Epidemiol Rev 1998;20:137–147.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Edward J. Boyko
  • Nicholas L. Smith
  • Jessie H. Ahroni

There are no affiliations available

Personalised recommendations